# Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region

> **NCT07370207** · PHASE2 · RECRUITING · sponsor: **AusperBio Therapeutics Inc.** · enrollment: 84 (estimated)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** AHB-137

## Key facts

- **NCT ID:** NCT07370207
- **Lead sponsor:** AusperBio Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-06
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07370207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07370207, "Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07370207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*